Physician profile
Danielle Mitchel
NPI 1043779309
$1,586.92
in general payments reported to CMS, 2019-2025
15 companies · $724 in 2025
The $724 reported for 2025 was more than what 84% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $337 · 2023: $16.52 · 2024: $397 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082 · Education: $55.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,082.25 |
| Education | $55.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $375.72 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Ipsen Biopharmaceuticals, INC | $259.85 | 2021-2022 | |
| Tg Therapeutics, INC. | $158.12 | 2024-2025 | |
| Penumbra, INC. | $137.84 | 2024 | Indigo System |
| Astrazeneca Pharmaceuticals Lp | $113.95 | 2025 | Wainua |
| Janssen Biotech, INC. | $111.10 | 2025 | |
| Spr Therapeutics, INC | $109.76 | 2022 | |
| Merz Pharmaceuticals, LLC | $79.56 | 2022 | |
| Alexion Pharmaceuticals, INC. | $74.88 | 2025 | Ultomiris |
| Biogen, INC. | $48.44 | 2025 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $30.81 | 2025 | |
| Cycle Pharmaceuticals INC | $26.80 | 2025 | Bafiertam |
| Genentech USA, INC. | $25.04 | 2024 | Ocrevus Zunovo |
| Banner Life Sciences, LLC | $18.53 | 2024 | |
| Piramal Critical Care | $16.52 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Mitchel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.